Skip to main content

Meeting Highlights

Meeting Highlights

Nivolumab plus Azacitidine Shows Encouraging Activity in R/R AML or as Frontline Therapy in Elderly Patients with AML

Meeting Highlights

Safety and Tolerability of Midostaurin from Expanded Treatment Protocol in Patients with FLT3 Mutation–Positive, Newly Diagnosed AML

Meeting Highlights

Encouraging Efficacy and Safety with Enasidenib or Ivosidenib plus Azacitidine in Patients with Newly Diagnosed AML

Meeting Highlights

Enasidenib Monotherapy Is Well-Tolerated and Active in Older Patients with Untreated mIDH2 AML

Meeting Highlights

Long-Term Tolerability of Olaparib Tablets as Maintenance Therapy for Platinum-Sensitive Relapsed Ovarian Cancer

Meeting Highlights

Effect of Prior Chemotherapy Regimens on Rucaparib Treatment in Platinum-Sensitive Recurrent Ovarian Carcinoma

Meeting Highlights

Phase 3 Trial of Lurbinectedin vs Pegylated Liposomal Doxorubicin or Topotecan in Platinum-Resistant Ovarian Cancer Patients

Meeting Highlights

Carboplatin/Pegylated Liposomal Doxorubicin/Bevacizumab vs Carboplatin/Gemcitabine/Bevacizumab in Patients with Recurrent Ovarian Cancer

Meeting Highlights

Psychological Support vs Standard of Care Following Chemotherapy for Ovarian Cancer

Meeting Highlights

A Phase 1/2 Study of Chemo-Immunotherapy with Durvalumab and Pegylated Liposomal Doxorubicin (PLD) in Platinum-Resistant Recurrent Ovarian Cancer

1
2
3
4

Page 1 of 17
Results 1 - 10 of 169